Ubrelvy

Product Monograph

PATIENT INFORMATION

Important Safety Information

UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

●Contraindications with concomitant use of strong CYP3A4 inhibitors.

●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breastfeeding women and dose selection in geriatric patients.

●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011.

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

●Contraindications with concomitant use of strong CYP3A4 inhibitors.

●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011.

SAFETY INFORMATION

Click here for additional safety information and for a link to the Product Monograph discussing:

●Contraindications with concomitant use of strong CYP3A4 inhibitors.

●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

FOR MORE INFORMATION

For any questions related to UBRELVY, you can contact AbbVie Medical Information at
1-844-241-5011.

CGRP=calcitonin gene-related peptide.

* Comparative clinical significance unknown. 

References:

1. UBRELVY (ubrogepant) Product Monograph. AbbVie Corporation.

2. Data on File, AbbVie Corporation.

3. “Summary Basis of Decision – Ubrelvy”. Health Canada. Updated March 30, 2023. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00631 (accessed April 19, 2023).

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.

CA-UBR-260029A / JN26

UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.

CA-UBR-260029A / JN26